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AbstrAct
Introduction The aim of this cohort study was to examine 
health-related quality of life (HRQoL) and symptomatology 
in patients with pulmonary hypertension (PH) and explore 
factors that influence its evolution over time.
Methods A prospective longitudinal multisite cohort study. 
Participants were recruited from specialist UK PH centres 
and completed a questionnaire pack at baseline, 6, 12 and 
18 months to assess HRQoL (emPHasis-10), dyspnoea, 
fatigue, sleep, anxiety and depression.
results 185 patients entered the study at baseline and 
126 (68%) completed month 18. At baseline, patients 
had significant impairment of HRQoL, anxiety, depression, 
dyspnoea and severe fatigue. No significant changes, apart 
from a reduction in the Hospital Anxiety and Depression 
Scale-Anxiety score (P=0.04), were observed over 
18 months. Depression and dyspnoea were predictors of 
HRQoL (P=0.002 and P=0.03, respectively). Oxygen use 
was also associated with diminished HRQoL and increased 
symptom severity.
conclusion Patients with PH experience high levels of 
symptom severity and the negative impact on HRQoL 
was unchanged over time. The use of oxygen therapy, in 
particular, was associated with a significant impact on 
HRQoL. Further study of factors impacting HRQoL and 
interventions that target a combination of physiological and 
psychosocial consequences of living with PH are needed.
IntroductIon
Pulmonary hypertension (PH) is an umbrella 
term used to describe a rare heterogeneous 
group of diseases defined at cardiac catheteri-
sation as a mean pulmonary artery pressure of 
at least 25 mm Hg.1 It ranges from mild eleva-
tions of pulmonary artery pressure frequently 
seen in the context of severe cardiac and 
respiratory disease to severe elevations of 
pulmonary artery pressure seen in patients 
with rare forms of PH such as pulmonary 
arterial hypertension and chronic thrombo-
embolic pulmonary hypertension. It is clas-
sified into the following five separate groups 
according to similar clinical, pathological 
and haemodynamic characteristics: Group 1 
refers to the subtypes of pulmonary hyper-
tension associated with abnormalities in the 
arterioles, the small branches of the pulmo-
nary arteries, such as idiopathic pulmonary 
hypertension; Groups 2 and 3 refer to PH 
caused by left heart disease and lung disease, 
respectively; Group 4 refers to PH secondary 
to chronic thromboembolic PH; and Group 
5 includes other less common causes that 
do not fit into any of the other four groups.1 
In this paper, the term PH is used to denote 
Groups 1, 4 and 5.
Patients present with a range of symptoms, 
which are typically related to right ventricular 
dysfunction, and include dyspnoea, fatigue, 
weakness, chest pain and syncope.1 2 Symp-
toms are present on physical exertion, and 
as the condition progresses, symptoms often 
occur at rest and affect health-related quality 
of life (HRQoL).1–4 Psychological symptoms 
such as anxiety, depression and panic disor-
ders have also been reported.5–12
Key messages
 ► Although people with PH may be living for 
longer, they are doing so under the weight of a 
considerable burden of symptoms that negatively 
impacts health-related quality of life.
 ► The use of oxygen therapy, in particular, is 
associated with self-reported symptom severity and 
poorer health-related quality of life.
 ► Recognizing the importance of these symptoms and 
the need for their regular assessment may help us 
to offer specific interventions to patients to help 
improve or maintain health-related quality of life in 
the long term. 
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Since there is currently no available cure, treatment 
is aimed at alleviating symptoms and slowing disease 
progression.1 Although recent advances in pharmaco-
therapy have led to improved survival rates and slower 
disease progression,13–15 the symptom burden of PH 
remains high.3 8 16 In addition, treatment may be asso-
ciated with adverse reactions that can have a significant 
negative effect on HRQoL.16–18
In the past, assessment of patients with PH relied on 
functional and haemodynamic measurements. However, 
the importance of HRQoL is becoming increasingly 
recognised.5–7 19–21 Since HRQoL is a measure of 
overall well-being, it is affected by both physical and 
mental factors, and studies in patients with PH indi-
cate that both these domains of HRQoL are substan-
tially impaired in patients with PH,6 7 20 22 the degree of 
impairment becoming greater as functional class (FC) 
increases.22 23 Health-related quality of life has also been 
shown to correlate with survival in patients with PH.24–26 
Qualitative and cross-sectional studies carried out to 
describe patients’ experiences of living with PH have 
illustrated its impact on their lives and their need/ability 
to adapt their lifestyles to the condition over time.8 16 18
In a survey conducted by the European Pulmonary 
Hypertension Association of 455 patients and carers in 
five countries,23 over half of patients reported that PH 
had a significant impact on daily life: for example, taking 
part in exercise or sport, climbing stairs and performing 
everyday tasks such as housework or food shopping. 
Work and employment were major issues, with their 
consequent effect on household income and personal 
relationships. The US Food and Drug Administration’s 
Voice of the Patient initiative also underlined the chronic 
and debilitating effect of PH on patients’ lives and the 
difficulties they experience in finding effective and toler-
able treatments.17
Most studies that have investigated the patient’s expe-
rience of living with PH and its effect on HRQoL have 
been cross-sectional, and long-term longitudinal data are 
currently lacking. The aim of this study was to examine 
various aspects of patient-reported HRQoL over an 
18-month period in patients living with PH and to explore 
which factors predict a decline in HRQoL over time.
Methods
Participants
Patients aged 18 years or more who had a medically 
confirmed diagnosis of PH and were being treated at a 
UK specialist centre were eligible for enrolment in this 
prospective longitudinal cohort study. Those with chronic 
thromboembolic disease suitable for surgery (or who had 
received successful surgery), terminal disease and/or 
severe and enduring mental illness were excluded from 
the study.
As multilevel regression was used for quantitative anal-
ysis, and several models were fitted, sample size was calcu-
lated using rule of thumb for regression.27 A sample size 
of 194 was considered sufficient to fit a model with up 
to 18 independent variables, assuming medium-sized 
relationships between the dependent variable and the 
independent variables, 5% significance and 80% power. 
The recruitment target was 240 participants to allow for a 
minimum of 15% attrition throughout the study.
Participants were recruited between July 2013 and 
January 2014, from across all UK specialist PH centres 
(n=8) and via the Pulmonary Hypertension Association 
(PHA) UK research database, and followed for 18 months. 
They were approached during their routine clinic visit or 
via an invitation letter sent to their home with a reply 
envelope addressed to PHA UK so that they could obtain 
further information about the study if they wished. Ques-
tionnaire packs were sent to the participant’s home for 
self-completion and return within 1 week. Appropriate 
ethical approval was granted (Ref: 13/NW/0345) and 
written informed consent was obtained prior to study 
entry.
data collection
Demographic and clinical data, including age, gender, 
diagnosis, time since diagnosis, medications, comor-
bidities, oxygen use and 6 min walk/shuttle test, were 
extracted from the participant’s notes at recruitment, 
and at 6, 12 and 18 months, if available (patients with 
PH generally visit their specialist centre for review at 
6-month intervals). Participants also completed the ques-
tionnaires outlined in table 1 at the same 6-month inter-
vals to explore a range of HRQoL and symptom-related 
variables.
data analysis
Data were analysed using Stata V.13.1. Statistical signif-
icance was set at <0.05. Clinical and demographic data 
analyses were descriptive. Questionnaire scores were 
calculated according to corresponding scoring algo-
rithms, and multilevel regression methods were used to 
examine the changes in the various scores between the 
four time points. Two-level models were used with indi-
vidual measurements nested within participants. The χ2 
test, unpaired t-test and Mann-Whitney U test were used 
to compare differences in factors between dropouts and 
non-dropouts. Subsequently, multiple logistic regression 
analysis was performed to examine the joint association 
with dropout, using backwards selection to retain impor-
tant variables only.
Multilevel linear regression was used to explore factors 
associated with HRQoL, and associations between each 
predictor variable and emPHasis-10 using data from all 
time points. First, a series of analyses was performed for 
each factor, with and without adjustments for diagnosis, 
age and gender. Subsequently, the associations between 
predictor variables and emPHasis-10 score were exam-
ined, also adjusted for diagnosis, age and gender, using 
backwards selection to retain statistically significant 
factors only. Multilevel regression methods were also 
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used to compare oxygen use for measurements from all 
time points combined for participants not using oxygen 
‘at all’ with a combined group using oxygen ‘night-time 
only’/‘as I need it’/‘all of the time’.
results
Participant demographics
Questionnaires were sent to 262 patients. Of these, 
185 were returned at baseline (70% response), 153 at 
6 months, 140 at 12 months and 126 at 18 months, giving 
a rate of attrition of 32% by the end of the study.
Patient demographics are shown in table 2. Mean 
patient age was 56 years, 68% were women, most had 
Group 1 PH (133, 73%; of whom 66, 36% were idiopathic 
pulmonary arterial hypertension (PAH)) and 39% were 
on PH monotherapy, and 51% on combination therapy 
with 13% on parenteral prostanoid. There were no statis-
tically significant differences in any of the patient-re-
ported measures at baseline and follow-up between the 
different PH diagnostic groups.
Few participants lived alone (16%) or were in full-time 
employment (9%). The majority reported WHO FC II 
(34%) or III (42%) at baseline.
There were missing data for the walk test results at 
each time point: baseline missing data for 32/185 (17%) 
of patients; 6 months missing data for 77/153 (50%) of 
patients still in the study at this time point; 12 months 
missing data for 68/140 (49%) of patients still in the study 
at this time point; and 18 months missing data for 60/126 
(48%) of patients still in the study at this time point. This 
prevented meaningful analyses to be conducted to test 
correlations between decline/improvement in walk tests 
and HRQoL or symptom experience over time.
changes in test and questionnaire scores over time
Multilevel regression was used to assess the changes in test 
and questionnaire scores over time, and these are shown 
in table 3. Scores for fatigue were more than double 
the normative scores at baseline and were higher than 
reported cut-off values for chronic fatigue syndrome.28 
No significant changes in test or questionnaire scores 
were observed over 18 months, apart from a significant 
reduction in the HADS-Anxiety score (P=0.04), indi-
cating a slight decrease in emotional distress from base-
line (table 3).
Factors associated with attrition
A total of 59 participants (32%) dropped out of the 
study between baseline and 18 months (deaths n=11 and 
received a transplant n=4). These patients had signifi-
cantly higher WHO FC (P=0.02; table 4), and HADS-De-
pression and Dyspnoea-12 scores (P=0.002 and P=0.03, 
respectively; table 4). When the joint association between 
these factors and dropout was examined, only the 
HADS-Depression score was significantly associated with 
dropout, higher scores being associated with a greater 
risk of dropout (OR 1.14; 95% CI 1.05 to 1.24). Following 
adjustment for HADS-Depression score, neither WHO 
FC nor Dyspnoea-12 score had any additional effect on 
study discontinuation.
Factors associated with emPhasis-10 score
When analysed separately, scores for Dyspnoea-12, FSS, 
MOS-Sleep Index, HADS-Anxiety, HADS-Depression 
and patient-reported WHO FC were significantly asso-
ciated with HRQoL (emPHasis-10; all P<0.001), higher 
Table 1 Tests and questionnaires analysed in the study
emPHasis-10 This PH-specific HRQoL questionnaire consists of 10 items, each on a scale of 0–5. Scores range 
from 0 to 50, higher scores indicating poorer health status. For the purposes of this study, the key 
assessment is a change in score over time that may indicate that an individual’s condition has improved 
(lower score) or deteriorated (higher score)38
Dyspnoea-12 Each item in this 12-item questionnaire scores from 0 (never) to 3 (severe). It examines specific aspects 
of dyspnoea, with an emphasis on how people physically perceive the sensation and its emotional 
consequences. It uses simple summation scoring to provide scores from 0 to 36, higher scores 
corresponding to greater shortness of breath. The questionnaire has been validated for use in a number 
of cardiopulmonary conditions39
Fatigue Severity 
Scale 
This nine-item questionnaire was developed to evaluate disabling fatigue. Each item is rated on a seven-
point Likert scale, which ranges from strongly disagree to strongly agree. All nine items are combined 
into a total score, higher total scores indicating a more pronounced effect of fatigue on everyday life40
Medical Outcomes 
Study Sleep Index 
(MOS-Sleep Index)
The Sleep Problems Index used in this study consists of nine items that originate from the MOS-Sleep 
Scale. It assesses initiation (time to fall asleep), quantity (hours of sleep each night), maintenance, 
perceived adequacy, respiratory problems and somnolence. Scores are converted into 1–100, higher 
scores being indicative of worse sleep29
Hospital Anxiety and 
Depression Scale
A widely used tool that assesses psychological distress (seven items measure anxiety, the score ranging 
from 0 to 21; and seven items measure depression, the score ranging from 0 to 21); higher scores 
indicate greater emotional distress, and scores >8 suggest the presence of clinically relevant anxiety/
depression41
HRQoL, health-related quality of life; PH, pulmonary hypertension.
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scores reflecting poorer HRQoL (table 5). Significance 
was attained both with and without adjustment for 
diagnosis, age and gender. When included in the same 
model, Dyspnoea-12, FSS, HADS-Anxiety, HADS-De-
pression and WHO FC were predictors of HRQoL, each 
significantly associated with emPHasis-10 score (P<0.001; 
table 6). After adjustment for other variables, the rela-
tionship between the MOS-Sleep Index and emPHasis-10 
was statistically non-significant. The association between 
HADS-Depression score and emPHasis-10 score was linear 
after adjustment, with a unit increase in the former corre-
sponding to an average 0.5 unit increase in the latter.
comparisons of scores with and without oxygen
Thirty-nine participants (21%) were receiving oxygen at 
the start of the study, six of whom used oxygen contin-
uously. Multilevel regression demonstrated that those 
using oxygen had significantly higher emPHasis-10, 
FSS, HADS-Anxiety, HADS-Depression and Dyspnoea-12 
scores (table 7). The need for oxygen had no significant 
effect on participants’ sleep pattern (MOS-Sleep Index).
dIscussIon
To our knowledge, this is the first longitudinal, prospec-
tive, large cohort study to assess important symptom-based 
variables in PH and to examine how they affect HRQoL 
in real-life clinical practice. We have shown that although 
patients may be living for longer, they are doing so 
Table 2 Patient demographics
Demographic
Patients (n=185)
n (%)
Mean age, years (SD) 56.0 (13.1)
Mean 6 min walk test, metres (SD) 365 (146)*
Mean incremental shuttle walk test, 
metres (SD)
298 (198)*
Gender
  Male 59 (32)
  Female 126 (68)
PH diagnosis
  Idiopathic PAH 66 (36)
  CTEPH 20 (11)
  CTD PAH 32 (18)
  Congenital PAH 35 (19)
  Familial PH 2 (1)
  Other 6 (3)
  Unsure 21 (12)
Lives with
  Family 140 (76)
  Alone 30 (16)
  Friends 3 (2)
  Other 11 (6)
Employment
  Full time 17 (9)
  Part time 26 (14)
  Not employed 61 (34)
  Retired 77 (43)
WHO FC (patient reported)
  Class I 8 (5)
  Class II 60 (34)
  Class III 75 (42)
  Class IV 34 (19)
HADS-Anxiety score
  0–7 360 (61)
  8–10 108 (18)
  11–14 89 (15)
  15–21 32 (5)
HADS-Depression score
  0–7 426 (73)
  8–10 103 (18)
  11–14 47 (8)
  15–21 11 (2)
Oxygen
  Not at all 111 (61)
  Night-time only 19 (10)
  As I need it 25 (14)
Continued
Demographic
Patients (n=185)
n (%)
  All of the time 27 (15)
Therapy
  Single 70 (39)
  Dual 92 (51)
  Triple 11 (6)
  No treatment 7 (4)
Nebuliser therapy
  No 165 (93)
  Yes 13 (7)
Subcutaneous therapy
  No 173 (97)
  Yes 5 (3)
Intravenous therapy
  No 173 (97)
  Yes 5 (3)
*Baseline values for the 6 min walk test and incremental shuttle 
walk test were missing in 31 and 10 patients, respectively.
CTD, connective tissue disease; CTEPH, chronic thromboembolic 
pulmonary hypertension; HADS, Hospital Anxiety and Depression 
Scale; PAH, pulmonary arterial hypertension; PH, pulmonary 
hypertension; WHO FC, WHO functional class.
Table 2 Continued 
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under the weight of a considerable burden of symptoms. 
Despite improvements in survival of patients with PH, 
this study has illustrated that symptom severity is high, 
and although there were improvements in anxiety, the 
negative impact on HRQoL was unchanged over time. 
This highlights the need for further study of factors 
influencing, and additional interventions to manage, the 
impact of this chronic condition on HRQoL.
The association between HRQoL, as measured by 
emPHasis-10, and breathlessness, fatigue, depression, 
anxiety and sleep was assessed over time, and a strong 
relationship was demonstrated between each of these 
factors and HRQoL, particularly between HRQoL 
and breathlessness and depression. These findings 
are in line with those reported by Matura et al,21 who 
conducted a cross-sectional study to look at interfer-
ence of symptoms with HRQoL in patients with PH and 
found that breathlessness on exertion, fatigue and diffi-
culty in sleeping had the greatest effect on daily life in 
these patients.
Dyspnoea, fatigue, anxiety, depression, WHO FC and 
poor sleep were all found to be predictors of reduced 
HRQoL, as assessed by emPHasis-10. Following regres-
sion analysis, the relationship between poor sleep and 
HRQoL was no longer significant. Sleep quality in the 
sample was poor overall, with a mean MOS-Sleep score 
greater than 35 points,29 at all time points. Many of the 
factors affecting HRQoL, such as physical and psycholog-
ical symptoms, may have also affected quality of sleep in 
these patients.
Table 3 Changes in questionnaire scores over time
Score Baseline (n=185) 6 months (n=153) 12 months (n=140) 18 months (n=126) P value
emPHasis-10 27.0 (12.0) 25.8 (11.6) 25.4 (11.8) 25.4 (12.3) 0.54
Dyspnoea-12 11.5 (9.4) 10.5 (9.2) 10.3 (8.8) 10.8 (9.2) 0.20
FSS 5.1 (1.6) 4.8 (1.6) 4.8 (1.6) 4.7 (1.7) 0.07
MOS-Sleep Index 39.4 (19.2) 38.8 (20.0) 37.7 (19.0) 39.4 (19.7) 0.48
HADS-Anxiety 7.1 (4.7) 6.3 (4.4) 6.3 (4.3) 6.6 (4.5) 0.04
HADS-Depression 6.0 (3.8) 5.4 (3.8) 5.2 (3.5) 5.3 (3.6) 0.39
Multilevel regression methods were used to examine changes in the various scores among the four time points. Figures reported are the 
mean (SD) score at each time point.  
FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; MOS, Medical Outcomes Study.
Table 4 Factors associated with dropout
Variable No dropout (n=126) Dropout (n=59) P value
Mean age, years (SD) 55.5 (13.7) 57.0 (11.6) 0.47
Gender, n (%) 0.08
  Male 35 (28) 24 (41)
  Female 91 (72) 35 (59)
PH diagnosis, n (%) 0.69
  Idiopathic PH 49 (39) 17 (30)
  CTEPH 14 (11) 6 (11)
  CTD 19 (15) 13 (23)
  Congenital PH 24 (19) 11 (20)
  Other 20 (16) 12 (16)
Median Dyspnoea-12 score (IQR) 9 (2–16) 14 (5–19) 0.03
Median FSS score (IQR) 5.2 (3.8–6.2) 5.6 (4.6–6.6) 0.14
Mean HADS-Anxiety score (SD) 6.8 (4.5) 7.9 (5.0) 0.16
Mean HADS-Depression score (SD) 5.4 (3.6) 7.3 (4.1) 0.002
Mean MOS-Sleep Index score (SD) 37.7 (19.1) 43.2 (19.0) 0.08
WHO FC, n (%) 0.02
  Class I/II 53 (43) 15 (27)
  Class III 52 (43) 23 (42)
  Class IV 17 (14) 17 (31)
CTD, connective tissue disease; CTEPH, chronic thromboembolic pulmonary hypertension; FSS, Fatigue Severity Scale; HADS, Hospital 
Anxiety and Depression Scale; MOS, Medical Outcomes Study; PH, pulmonary hypertension; WHO FC, WHO functional class.
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Talwar et al30 carried out a retrospective study in 36 
patients with PH to examine the relationships between 
dyspnoea, depression and HRQoL using the generic SF-36 
scale (36-item Short Form Health Survey) and found a 
non-linear, negative relationship between the physical 
and mental components of this scale, perceived dyspnoea 
increasing with the severity of depression. However, in 
contrast to our findings, they observed that the SF-36 
mental component did not worsen until a certain severity 
of dyspnoea and depression was reached. An earlier study 
that used several scales to measure dyspnoea and depres-
sion in patients with chronic respiratory disease observed 
that depression was a significant predictor (P<0.05) of 
self-rated dyspnoea.31
Further research including patients with severe disease 
is needed, particularly as those with worse WHO FC, and 
high dyspnoea or depression scores were more likely 
to drop out of the study. Depression is a key variable 
as it continued to be associated with patient dropout 
after other factors, including dyspnoea, had been 
excluded. Depression was also clearly associated with the 
emPHasis-10 score. The non-significant decline in most 
study variables, apart from anxiety, may have reached 
significance if those with worse WHO FC and depression 
were retained in the study.
Oxygen use was associated with significant impair-
ment in HRQoL and a significant increase in all symp-
toms assessed in the study (P≤0.001), apart from sleep. 
Previous studies have also found oxygen use to be asso-
ciated with reduced HRQoL. Although patients with PH 
may adapt to oxygen therapy over time,32 it is cumber-
some to use and places restrictions on patients’ daily lives 
that can lead to reduced HRQoL. Previous investigations 
into patients’ experiences of living with PH reported that 
having to use oxygen therapy was more distressing to 
them than other aspects of treatment, including use of 
intravenous medications.18
Table 5 Association between individual predictor factors and emPHasis-10 scores (n=126)
Variable Category/term
Unadjusted Adjusted*
Coefficient (95% CI) P value Coefficient (95% CI) P value
Dyspnoea-12† Linear term 6.5 (5.4 to 7.6) <0.001 6.7 (5.6 to 7.9) <0.001
Squared term −0.4 (−0.6 to 0.2) −0.4 (−0.6 to 0.2)
MOS-Sleep Index‡ – 1.7 (1.2 to 2.2) <0.001 1.7 (1.2 to 2.2) <0.001
FSS† – 3.2 (2.8 to 3.7) <0.001 3.3 (2.8 to 3.7) <0.001
HADS-Anxiety – 1.1 (0.9 to 1.3) <0.001 1.1 (0.9 to 1.3) <0.001
HADS-Depression Linear term 2.2 (1.6 to 2.7) <0.001 2.2 (1.7 to 2.8) <0.001
Squared term −0.06 (−0.09 to 0.02) −0.06 (−0.09 to 0.02)
WHO FC (patient reported) FC I/II 0 <0.001 0 <0.001
FC III 5.1 (3.7 to 6.6) 5.3 (3.8 to 6.7)
FC IV 7.5 (5.4 to 9.5) 7.5 (5.4 to 9.6)
*Adjusted for diagnosis, age and gender.
†Regression coefficients reported for a 5-unit increase in predictor variable.
‡Regression coefficients reported for a 10-unit increase in predictor variable.
FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; MOS, Medical Outcomes Study; WHO FC, WHO functional 
class.
Table 6 Association between combined predictor factors and emPHasis-10 scores (n=126)
Variable Category/term Coefficient (95% CI)* P value
Dyspnoea-12† Linear term 4.5 (3.4 to 5.6) <0.001
Squared term −0.4 (−0.6 to −0.2)
FSS† – 1.7 (1.3 to  2.2) <0.001
HADS-Anxiety – 0.3 (0.1 to 0.5) 0.001
HADS-Depression – 0.5 (0.3 to 0.8) <0.001
WHO FC (patient reported) FC I/II 0 <0.001
FC III 2.5 (1.2 to 3.8)
FC IV 2.9 (1.0 to 4.7)
*Adjusted for diagnosis, age and gender.
†Regression coefficients reported for a 5-unit increase in predictor variable.
FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; WHO FC, WHO functional class.
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Studies in patients with chronic obstructive pulmo-
nary disease (COPD) or interstitial lung disease (ILD) 
have reported similar findings. A study that compared 
oxygen-dependent patients with COPD with matched 
control patients with COPD found that all domains of 
HRQoL (SF-36 score) were profoundly impaired in 
oxygen-dependent patients compared with the control 
group.33 In qualitative studies, patients with COPD stated 
their dislike of carrying and maintaining oxygen equip-
ment, many relying on their carer to carry the equipment 
when they ventured outside. They were embarrassed 
about using oxygen in public, distressed at losing their 
independence and worried that their oxygen would 
run out if they left the house.34 35 Similar concerns were 
expressed by patients with ILD, who highlighted the prac-
tical challenges of oxygen therapy, loss of independence, 
social stigma and restrictions on their lifestyles.36 37 This 
highlights the need for further study with respect to the 
efficacy and impact of oxygen therapy in patients with PH 
and cautions against its indiscriminate use.
Our study is based on participants completing ques-
tionnaires sent to their home for self-completion and 
return within 1 week. This approach has weaknesses 
with a significant number of missing data over time. 
Furthermore, it was not possible to always link self-com-
pleted outcomes with objective measures such as walk 
distance tests, extracted from patient records—these 
were often weeks apart with significant levels of missing 
data. A limitation of this study is that although patients 
from all WHO FCs were recruited to the study, 76% of 
participants were in FC II or III (patient reported) on 
enrolment and over 90% were receiving oral therapy, 
and therefore few data were available for patients in stage 
IV PH. In addition, participants with a higher FC were 
more likely to drop out of the study, further reducing the 
amount of study information on patients who were no 
longer receiving oral therapy and who may have specific 
HRQoL issues. Finally, longer follow-up including the 
collection of patient self-report outcomes and objective 
clinical measures concurrently is needed to assess how 
HRQoL and symptom severity evolves as time goes on.
This study has highlighted a number of key factors, 
including dyspnoea, depression, anxiety, fatigue and 
quality of sleep that may predict a decline in HRQoL 
over time in patients with PH. Recognising the impor-
tance of these symptoms and the need for their regular 
assessment may help us to offer specific interventions to 
patients, as appropriate, to help improve or maintain 
HRQoL in the long term.
Acknowledgements We are grateful to Cath Billings for comments on early 
manuscript drafts. Editorial assistance was provided by Solaris Health.
contributors JY and IA conceived the original study idea. JY, IA, CD, LMcG, MC, 
PS and DGK all contributed to the study design, data analysis and interpretation. PS 
collected data. All authors contributed to the preparation of the manuscript. 
Funding Funding received by the Pulmonary Hypertension Association UK. 
competing interests None declared.
Patient consent Obtained.
ethics approval North West—Lancaster 13/NW/0245. 
Provenance and peer review Not commissioned; externally peer reviewed.
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
RefeRenCes
 1. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines 
for the diagnosis and treatment of pulmonary hypertension. Eur 
Respir J 2015;46:903–75.
 2. Armstrong I, Rochnia N, Harries C, et al. The trajectory to diagnosis 
with pulmonary arterial hypertension: a qualitative study. BMJ Open 
2012;2:e000806.
 3. Delcroix M, Howard L. Pulmonary arterial hypertension: the 
burden of disease and impact on quality of life. Eur Respir Rev 
2015;24:621–9.
 4. Cenedese E, Speich R, Dorschner L, et al. Measurement of quality 
of life in pulmonary hypertension and its significance. Eur Respir J 
2006;28:808–15.
Table 7 Associations between outcomes and oxygen usage
Variable* No oxygen (n=111) Oxygen (n=xx71) Difference (95% CI) P value†
Mean emPHasis-10 score (SD)‡ 22.5 (12.0) 32.5 (8.4) 7.4 (5.0 to 9.9) <0.001
Mean FSS score (SD)‡ 4.5 (1.7) 5.5 (1.4) 0.8 (0.5 to 1.2) <0.001
Mean MOS-Sleep Index (SD)‡ 37.2 (19.6) 42.2 (18.6) 3.1 (−1.2 to 7.4) 0.16
Mean HADS-Anxiety score (SD)‡ 5.8 (4.4) 8.0 (4.3) 1.6 (0.7 to 2.6) 0.001
Mean HADS-Depression score (SD)‡ 4.6 (3.4) 7.1 (3.7) 1.7 (0.9 to 2.5) <0.001
Median Dyspnoea-12 score (IQR)§ 6 (1–14) 15 (9–22) 1.93 (1.55 to 2.42) <0.001
*Mean values for total scores across all time points combined.
†P values indicate significance of the overall difference between the four time points.
‡For variables found to be approximately normally distributed, mean and SD were summarised: mean difference using oxygen versus no 
oxygen.
§For the variable found to be non-normally distributed, the median and IQR preferred was summarised, and the ratio of scores in participants 
using oxygen versus no oxygen is reported on a log scale.
FSS, Fatigue Severity Scale; HADS, Hospital Anxiety and Depression Scale; MOS, Medical Outcomes Study.
 o
n
 4 June 2018 by guest. Protected by copyright.
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2017-000263 on 1 March 2018. Downloaded from 
8 Yorke J, et al. BMJ Open Resp Res 2018;5:e000263. doi:10.1136/bmjresp-2017-000263
Open Access
 5. Löwe B, Gräfe K, Ufer C, et al. Anxiety and depression in patients 
with pulmonary hypertension. Psychosom Med 2004;66:831–6.
 6. Shafazand S, Goldstein MK, Doyle RL, et al. Health-related quality 
of life in patients with pulmonary arterial hypertension. Chest 
2004;126:1452–9.
 7. Taichman DB, Shin J, Hud L, et al. Health-related quality of life in 
patients with pulmonary arterial hypertension. Respir Res 2005;6:92.
 8. McDonough A, Matura LA, Carroll DL. Symptom experience 
of pulmonary arterial hypertension patients. Clin Nurs Res 
2011;20:120–34.
 9. White J, Hopkins RO, Glissmeyer EW, et al. Cognitive, emotional, 
and quality of life outcomes in patients with pulmonary arterial 
hypertension. Respir Res 2006;7:55.
 10. McCollister DH, Beutz M, McLaughlin V, et al. Depressive symptoms 
in pulmonary arterial hypertension: prevalence and association with 
functional status. Psychosomatics 2010;51:339–339.e8.
 11. Verma S, Cardenas-Garcia J, Mohapatra PR, et al. Depression in 
pulmonary arterial hypertension and interstitial lung diseases. N Am 
J Med Sci 2014;6:240–9.
 12. Looper KJ, Pierre A, Dunkley DM, et al. Depressive symptoms 
in relation to physical functioning in pulmonary hypertension. J 
Psychosom Res 2009;66:221–5.
 13. Galiè N, Barberà JA, Frost AE, et al. Initial use of ambrisentan 
plus tadalafil in pulmonary arterial hypertension. N Engl J Med 
2015;373:834–44.
 14. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity 
and mortality in pulmonary arterial hypertension. N Engl J Med 
2013;369:809–18.
 15. Sitbon O, Channick R, Chin KM, et al. Selexipag for the treatment of 
pulmonary arterial hypertension. N Engl J Med 2015;373:2522–33.
 16. Yorke J, Armstrong I, Bundock S. Impact of living with pulmonary 
hypertension: a qualitative exploration. Nurs Health Sci 
2014;16:454–60.
 17. U.S. Food and Drug Administration (FDA). The voice of the patient. 
A series of reports from the U.S. Food and Drug Administration's 
(FDA's) patient-focused development initiative. Pulmonary 
arterial hypertension. Last updated Dec 2014. https:/ /www.fda.
gov /download s/fo rind ustr y/us erfees/ prescriptiondrugus erfe e/ u 
cm429382. pdf (accessed 25 Jul 2017).
 18. Flattery MP, Pinson JM, Savage L, et al. Living with pulmonary artery 
hypertension: patients' experiences. Heart Lung 2005;34:99–107.
 19. Matura LA, McDonough A, Carroll DL. Predictors of health-
related quality of life in patients with idiopathic pulmonary arterial 
hypertension. J Hosp Palliat Nurs 2012;14:283–92.
 20. Matura LA, McDonough A, Carroll DL. Health-related quality of 
life and psychological states in patients with pulmonary arterial 
hypertension. J Cardiovasc Nurs 2014;29:178–84.
 21. Matura LA, McDonough A, Carroll DL. Symptom interference 
severity and health-related quality of life in pulmonary arterial 
hypertension. J Pain Symptom Manage 2016;51:25–32.
 22. Kukkonen M, Puhakka A, Halme M. Quality of life among pulmonary 
hypertension patients in Finland. Eur Clin Respir J 2016;3:26405.
 23. European Pulmonary Hypertension Association (PHA). The impact 
of pulmonary arterial hypertension (PAH) on the lives of patients 
and carers: results from an international survey. last updated Sep 
2012. http://www. phaeurope. org/ wp- content/ uploads/ International- 
PAH- patient- and- Carer- Survey- Report- FINAL1. pdf (accessed 25 Jul 
2017).
 24. Mathai SC, Suber T, Khair RM, et al. Health-related quality of life 
and survival in pulmonary arterial hypertension. Ann Am Thorac Soc 
2016;13:31–9.
 25. Blok IM, van Riel AC, Schuuring MJ, et al. Decrease in quality 
of life predicts mortality in adult patients with pulmonary arterial 
hypertension due to congenital heart disease. Neth Heart J 
2015;23:278–84.
 26. Rubenfire M, Lippo G, Bodini BD, et al. Evaluating health-related 
quality of life, work ability, and disability in pulmonary arterial 
hypertension: an unmet need. Chest 2009;136:597–603.
 27. Tabachnik BG, Fidell LS. Using multivariate statistics. 4th Edn. 
Needham Heights MA: Allyn and Bacon, 2001.
 28. Jason LA, Evans M, Brown M, et al. Fatigue scales and chronic 
fatigue syndrome: issues of sensitivity and specificity. Disabil Stud Q 
2011;31.
 29. Stewart AL, Hays RD, Ware JE. The MOS short-form general health 
survey. Reliability and validity in a patient population. Med Care 
1988;26:724–32.
 30. Talwar A, Sahni S, Kim EJ, et al. Dyspnea, depression and health 
related quality of life in pulmonary arterial hypertension patients. J 
Exerc Rehabil 2015;11:259–65.
 31. Kellner R, Samet J, Pathak D. Dyspnea, anxiety, and depression 
in chronic respiratory impairment. Gen Hosp Psychiatry 
1992;14:20–8.
 32. Cullen DL, Stiffler D. Long-term oxygen therapy: review from the 
patients' perspective. Chron Respir Dis 2009;6:141–7.
 33. Lacasse Y, Bernard S, Martin S, et al. Utility scores in patients 
with oxygen-dependent COPD: a case-control study. COPD 
2015;12:510–5.
 34. Arnold E, Bruton A, Donovan-Hall M, et al. Ambulatory oxygen: why 
do COPD patients not use their portable systems as prescribed? A 
qualitative study. BMC Pulm Med 2011;11:9.
 35. Goldbart J, Yohannes AM, Woolrych R, et al. 'It is not going to 
change his life but it has picked him up': a qualitative study of 
perspectives on long term oxygen therapy for people with chronic 
obstructive pulmonary disease. Health Qual Life Outcomes 
2013;11:124.
 36. Khor YH, Goh NSL, McDonald CF, et al. Oxygen therapy for 
interstitial lung disease. A mismatch between patient expectations 
and experiences. Ann Am Thorac Soc 2017;14:888–95.
 37. U.S. Food and Drug Administration (FDA). The voice of the patient. 
A series of reports from the U.S. Food and Drug Administration’s 
(FDA’s) patient-focused drug development initiative. Idiopathic 
pulmonary fibrosis. last updated Mar 2015. https:/ /www.fda.
gov /download s/fo rind ustr y/us erfees/ prescriptiondrugus erfe e/ u 
cm440829. pdf (accessed 25 Jul 2017).
 38. Yorke J, Corris P, Gaine S, et al. emPHasis-10: development of a 
health-related quality of life measure in pulmonary hypertension. Eur 
Respir J 2014;43:1106–13.
 39. Yorke J, Moosavi SH, Shuldham C, et al. Quantification of 
dyspnoea using descriptors: development and initial testing of the 
Dyspnoea-12. Thorax 2010;65:21–6.
 40. Krupp LB, LaRocca NG, Muir-Nash J, et al. The fatigue severity 
scale. Application to patients with multiple sclerosis and systemic 
lupus erythematosus. Arch Neurol 1989;46:1121–3.
 41. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. 
Acta Psychiatr Scand 1983;67:361–70.
 o
n
 4 June 2018 by guest. Protected by copyright.
http://bmjopenrespres.bmj.com/
BM
J O
pen Resp Res: first published as 10.1136/bmjresp-2017-000263 on 1 March 2018. Downloaded from 
